દુર્લભ બ્લડ કેન્સર (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different tre…

સ્પોન્સર: Immune Oncology Research Institute
ClinicalTrials.gov પર NCT05430971
રજિસ્ટ્રી પર છેલ્લે 5 Jun 2026 ના રોજ અપડેટ થયું · અમે 20 Oct 2026 ના રોજ વાંચ્યું